论文部分内容阅读
目的:考察肿瘤多药耐药逆转剂HZ08与阿霉素联用对阿霉素在大鼠体内药动学的影响。方法:采用LC-MS/MS法测定HZ08和阿霉素的血药浓度,以DAS 2.0软件计算药动学参数,大鼠尾静脉注射HZ08和阿霉素,与对照组分别单独注射阿霉素和HZ08以及阳性药组注射维拉帕米相比较,考察HZ08与阿霉素联用对阿霉素药动学影响。结果:HZ08未显著改变阿霉素的主要药动学参数,与阿霉素联合用药对HZ08自身在大鼠体内的药动学也无显著影响,阳性药维拉帕米则显著增加阿霉素药时曲线下面积(AUC)和血药峰浓度(Cmax)。结论:HZ08与阿霉素联用对阿霉素大鼠体内药动学无显著影响。
Objective: To investigate the effects of multidrug resistance reversal agents HZ08 and doxorubicin on the pharmacokinetics of doxorubicin in rats. Methods: The plasma concentrations of HZ08 and doxorubicin were determined by LC-MS / MS. The pharmacokinetic parameters were calculated by DAS 2.0 software. HZ08 and doxorubicin were injected into the caudal vein of rats, and adriamycin Compared with HZ08 and verapamil injection, we investigated the effect of HZ08 combined with doxorubicin on doxorubicin pharmacokinetics. Results: HZ08 did not significantly change the main pharmacokinetic parameters of doxorubicin, combined with doxorubicin on HZ08 itself pharmacokinetics in rats also had no significant effect, the positive drug verapamil was significantly increased doxorubicin Pharmacokinetic area under the curve (AUC) and peak blood concentration (Cmax). Conclusion: The combination of HZ08 and doxorubicin has no significant effect on the pharmacokinetics of doxorubicin in rats.